Atossa Genetics (ATOS) Earning Somewhat Favorable News Coverage, Analysis Finds
News headlines about Atossa Genetics (NASDAQ:ATOS) have trended somewhat positive on Friday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Atossa Genetics earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.7273784791736 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Atossa Genetics (NASDAQ ATOS) traded down 1.4639% on Friday, hitting $0.4779. 245,197 shares of the company’s stock traded hands. Atossa Genetics has a 1-year low of $0.32 and a 1-year high of $2.60. The company’s market cap is $5.59 million. The firm’s 50-day moving average price is $0.40 and its 200 day moving average price is $0.68.
Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by $0.20. On average, equities research analysts expect that Atossa Genetics will post ($3.57) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/08/atossa-genetics-atos-earning-somewhat-favorable-news-coverage-analysis-finds.html.
Atossa Genetics Company Profile
Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.
Receive News & Stock Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related stocks with our FREE daily email newsletter.